We previously described the radiosynthesis and preliminary biodistribution of 3-(3-(3-[F-18]fluoropropyl)thio)-1,2,5,thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine ([F-18]FP-TZTP, a muscarinic M2 selective ligand. In collaboration with NIMH investigators, we recently began studies in normal human volunteers, with the eventual goal of studying patients with Alzheimer?s disease. The initial analysis, based on data from six young control subjects, concentrated on the determination of the appropriate kinetic model for [F-18]FP-TZTP in humans. In plasma, parent compound represented 68 plus or minus 8, 41 plus or minus 9, and 14 plus or minus 4 percent of radioactivity at 20, 40, and 120 min, respectively. The plasma free fraction (fp) was 5.9 plus or minus 1.2 percent. A model with one tissue compartment produced an excellent fit for the full 120 min of data, so that the additional parameters of a two-compartment model were unidentifiable. K1 values in gray matter regions were high-0.36 to 0.56 ml/min/ml-and showed excellent correlation with CBF. V values, representing total tissue binding, were very similar in cortical regions, basal ganglia, and thalamus, but were significantly higher (p less than .01) in amygdala. Unlike the results in the monkey, binding in the cerebellum was similar to that in the cerebral cortex. V values correlated with fp and normalization of V by fp reduced the coefficient of variation of V from 24 to 16 percent. The methodology and results from our analysis of [F-18]FP-TZTP data in young controls provide the basis for ongoing studies in elderly controls and patients with Alzheimer's disease. Another goal is to develop a series of F-18-labeled radiopharmaceuticals that are serotonin 5-HT-1A subtype specific and have a range of binding affinities. We evaluated [F 18]FCWAY in rhesus monkeys with PET. The goal of these studies was to further develop [F-18]FCWAY as a radioligand to measure 5-HT-1A receptors in humans. Studies included control experiments to develop an appropriate kinetic model and preblocking studies to demonstrate specific binding and estimate the level of nonspecific binding. Separate experiments with injection of the labeled metabolites of [F-18]FCWAY were also performed to determine if significant brain accumulation occurred. Control [F-18]FCWAY studies were performed to assess the regional binding patterns. Like [C-11]WAY, [F-18]FCWAY showed a binding pattern consistent with 5-HT-1A binding, that is, the highest binding in the frontal and medial temporal cortex, intermediate binding in other cortical regions, low binding in the thalamus and caudate nuclei, and minimal uptake in the cerebellum. By 60 to 90 min post-injection, the frontal-to-cerebellum binding ratio was difference 10:1. Preblocking studies with WAY 100635 (200 nmol/kg) administered 5 min before [F-18]FCWAY administration showed complete removal of specific binding, that is, highly uniform low binding levels in all regions. Longer lived PET radionuclides (Br-76 and I-124) are also under development, along with the technetium isotope Tc-94m. We also continue to produce At-211 for use in alpha particle therapy.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000500-05
Application #
6543094
Study Section
(NPET)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Park, Luke S; Szajek, Lawrence P; Wong, Karen J et al. (2004) Semi-automated 86Y purification using a three-column system. Nucl Med Biol 31:297-301
Ma, Ying; Lang, Lixin; Kiesewetter, Dale O et al. (2004) Purification of the precursor for the automated radiosynthesis of [18F]FCWAY by counter-current chromatography. J Chromatogr A 1034:149-53
Eckelman, William C; Rice, Kenner C; Contoreggi, Carlo (2004) New tools to monitor stress using non-invasive PET imaging. Ann N Y Acad Sci 1018:487-94
Yao, Zhengsheng; Zhang, Meili; Garmestani, Kayhan et al. (2004) Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N"",N""'-tetraacetic acid-biotin. Clin Cancer Res 10:3137-46
Jagoda, E M; Vaquero, J J; Seidel, J et al. (2004) Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol 31:771-9
Neumeister, Alexander; Bain, Earle; Nugent, Allison C et al. (2004) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-91
Benson, Brenda E; Carson, Richard E; Kiesewetter, Dale O et al. (2004) A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology 29:1239-50
Giovacchini, Giampiero; Lerner, Alicja; Toczek, Maria T et al. (2004) Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 45:1471-9
Wesley, Jon N; McGee, Edwin C; Garmestani, Kayhan et al. (2004) Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. Nucl Med Biol 31:357-64
Shimoji, Kazuaki; Ravasi, Laura; Schmidt, Kathleen et al. (2004) Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling. J Nucl Med 45:665-72

Showing the most recent 10 out of 59 publications